Novel intermediate form of serotonin receptor identified as therapeutic target for psychiatric disorders

Misha Kudryshev’s lab at the Max Delbrück Center has identified a molecular intermediate of a serotonin receptor that is involved in diseases such as depression and schizophrenia.

Vertex, U.K. reach deal to provide CRISPR-based medicine to thalassemia patients in England

LONDON — Patients in England with a rare blood disorder will now be able to receive the world’s first CRISPR-based medicine, after drugmaker Vertex Pharmaceuticals

August 7, 2024

AltruBio secures $225m for ICE programme development

ALTB-268 is being analysed in a Phase IIa exploratory biomarker study targeting patients with ulcerative colitis. Credit: Jo Panuwat D / Shutterstock.com. AltruBio has secured

May 22, 2024

Ditch Sterile Gloves When Treating Wounds?

Use of sterile gloves might not be necessary to prevent infections when treating wounds, a meta-analysis of randomized trials found. Pooled results from four randomized

December 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.